Goodman Corey S's Form 4 filing
Checkmate Pharmaceuticals, Inc. (CMPI) · filed Apr 29, 2022
- Accession no.
- 0001567619-22-009203
- Filed
- Apr 29, 2022, 5:50 PM ET
- Trade date
- Apr 27-29, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.97M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Goodman Corey SCIK 0001278411 | 10% Owner |
| Adelman Robert JCIK 0001329161 | 10% Owner |
| venBio Global Strategic Fund II L.P.CIK 0001634632 | 10% Owner |
| venBio Global Strategic GP II, Ltd.CIK 0001729408 | 10% Owner |
| venBio Global Strategic GP II, L.P.CIK 0001729409 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 27, 2022 | Common Stock | SSaleDisposed | −47,396 | $10.38 | −$491,979.96 | 2,948,463 | Direct | |
| Apr 28, 2022 | Common Stock | SSaleDisposed | −73,400 | $10.38 | −$761,936.04 | 2,875,063 | Direct | |
| Apr 29, 2022 | Common Stock | SSaleDisposed | −69,230 | $10.38 | −$718,662.78 | 2,805,833 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.